Concomitant chemo-radio-immunotherapy has a lethal therapeutic effect on tongue carcinomas independent of the clinical stage and histological characteristics of the tumor

Oral Oncology

Volumn 42, Issue 9, 2006, Pages 873-879

  Yamamoto, Tetsuya ^a   Oku, Naohisa ^a   Tatemoto, Yukihiro ^b   Ueta, Eisaku ^a   Kamatani, Takaaki ^a   Sasabe, Eri ^a   Osaki, Tokio ^a  

^a KOCHI UNIVERSITY   (Japan)

^b Kochi Health Sciences Center   (Japan)

Author keywords

Concomitant chemo radio immunotherapy; Cyclin dependent kinase inhibitor p21; Proliferating cell nuclear antigen; Protein p53; Tongue carcinoma

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLINE; FLUOROURACIL; PEPLEOMYCIN; PICIBANIL; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL INVASION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MASTICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIDE EFFECT; SPEECH DISORDER; TONGUE CARCINOMA;

AGED; CARCINOMA, SQUAMOUS CELL; CELL DEATH; COMBINED MODALITY THERAPY; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MALE; MASTICATION; MIDDLE AGED; PROLIFERATING CELL NUCLEAR ANTIGEN; RETROSPECTIVE STUDIES; SPEECH PRODUCTION MEASUREMENT; SURVIVAL RATE; TONGUE NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33748890125     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2005.12.010     Document Type: Article

References (28)

1. Yamamoto T., Yoneda K., Ueta E., Tatemoto Y., and Osaki T. Combination adoptive immunotherapy with chemoradiotherapy in oral carcinomas. Int J Clin Oncol 1 (1996) 150-156
2. Huang S., Armstrong E.A., Benavente S., Chinnaiyan P., and Harari P.M. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 64 15 (2004) 5355-5362
3. Vattemi E., and Claudio P.P. Gene therapy for lung cancer: practice and promise. Ann Ital Chir 75 3 (2004) 279-289
4. Ervin T.J., Clark J.R., Weichselbaum R.R., Fallon B.G., Miller D., Fabian R.L., et al. An analysis of induction and adjuvant chemotherapy in the multidisciplinary treatment of squamous-cell carcinoma of the head and neck. J Clin Oncol 5 1 (1987) 10-20
5. Kerber C.W., Wong W.H., Howell S.B., Hanchett K., and Robbins K.T. An organ-preserving selective arterial chemotherapy strategy for head and neck cancer. AJNR Am J Neuroradiol 19 5 (1998) 935-941
6. Harrison L.B., and Fass D.E. Radiation therapy for oral cavity cancer. Dent Clin North Am 34 2 (1990) 205-222
7. Adelstein D.J., Sharan V.M., Earle A.S., Shah A.C., Vlastou C., Haria C.D., et al. Simultaneous versus sequential combined technique therapy for squamous cell head and neck cancer. Cancer 65 8 (1990) 1685-1691
8. Samant S., Kumar P., Wan J., Hanchett C., Vieira F., Murry T., et al. Concomitant radiation therapy and targeted cisplatin chemotherapy for the treatment of advanced pyriform sinus carcinoma: disease control and preservation of organ function. Head Neck 21 7 (1999) 595-601
9. Robbins K.T., Kumar P., Wong F.S., Hartsell W.F., Flick P., Palmer R., et al. Targeted chemoradiation for advanced head and neck cancer: analysis of 213 patients. Head Neck 22 7 (2000) 687-693
10. Newman L.A., Robbins K.T., Logemann J.A., Rademaker A.W., Lazarus C.L., Hamner A., et al. Swallowing and speech ability after treatment for head and neck cancer with targeted intraarterial versus intravenous chemoradiation. Head Neck 24 1 (2002) 68-77
11. Osaki T., Yoneda K., Hirota J., Yamamoto T., and Ueta E. Function-preserving surgery after induction therapy in tongue and floor of the mouth carcinomas. Asian J Oral Maxillofac Surg 6 (1994) 127-135
12. UICC: TNM classification of malignant tumors, 4th ed. Berlin: Springer-Verlag; 1987.
13. Jakobsson P.A., Eneroth C.M., Killander D., Moberger G., and Martensson B. Histologic classification and grading of malignancy in carcinoma of the larynx. Acta Radiol Ther Phys Biol 12 1 (1973) 1-8
14. Shimosato Y., Oboshi S., and Baba K. Histological evaluation of effects of radiotherapy and chemotherapy for carcinomas. Jpn J Clin Oncol 1 (1971) 19-35
15. Tomita Y., and Osaki T. Gustatory impairment and salivary gland pathophysiology in relation to oral cancer treatment. Int J Oral Maxillofac Surg 19 5 (1990) 299-304
16. Iwadate Y., Inoue M., Saegusa T., Tokusumi Y., Kinoh H., Hasegawa M., et al. Recombinant Sendai virus vector induces complete remission of established brain tumors through efficient interleukin-2 gene transfer in vaccinated rats. Clin Cancer Res 11 10 (2005) 3821-3827
17. Hynes N.E., and Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5 5 (2005) 341-354
18. Reboul F., Vincent P., Chauvet B., Brewer Y., Felix-Faure C., Taulelle M., et al. Radiation therapy with concomitant continuous infusion cisplatin for unresectable nonsmall cell lung carcinoma. Int J Radiat Oncol Biol Phys 28 5 (1994) 1251-1256
19. van den Broek G.B., Rasch C.R., Pameijer F.A., Peter E., van den Brekel M.W., Tan I.B., et al. Pretreatment probability model for predicting outcome after intraarterial chemoradiation for advanced head and neck carcinoma. Cancer 101 8 (2004) 1809-1817
20. Okamoto M., Ohe G., Oshikawa T., Nishikawa H., Furuichi S., Bando T., et al. Purification and characterization of cytokine-inducing protein of seed extract from Aeginetia indica L., a parasitic plant. Immunopharmacology 49 3 (2000) 377-389
21. Okamoto M., Furuichi S., Nishioka Y., Oshikawa T., Tano T., Ahmed S.U., et al. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation. Cancer Res 64 15 (2004) 5461-5470
22. Ueta E., Umazume M., Yamamoto T., and Osaki T. Enhancement of polymorphonuclear leukocyte (PMN) function by OK-432. Int J Immunopharmacol 16 1 (1994) 7-17
23. Mignogna M.D., Fedele S., Lo Russo L., Ruoppo E., and Lo Muzio L. Costs and effectiveness in the care of patients with oral and pharyngeal cancer: analysis of a paradox. Eur J Cancer Prev 11 3 (2002) 205-208
24. Nair K.S., Naidoo R., and Chetty R. Expression of cell adhesion molecules in oesophageal carcinoma and its prognostic value. J Clin Pathol 58 4 (2005) 343-351
25. Tatemoto Y., Osaki T., Yoneda K., Yamamoto T., Ueta E., and Kimura T. Expression of p53 and p21 proteins in oral squamous cell carcinoma: correlation with lymph node metastasis and response to chemoradiotherapy. Pathol Res Pract 194 12 (1998) 821-830
26. Golusinski W., Olofsson J., Szmeja Z., Biczysko W., Krygier-Stojalowska A., and Kulczynski B. A comprehensive analysis of selected diagnostic methods with respect to their usefulness in evaluating the biology of neoplastic cells in patients with laryngeal cancer. Eur Arch Otorhinolaryngol 256 6 (1999) 306-311
27. Osaki T., Kimura T., Tatemoto Y., Dapeng L., Yoneda K., and Yamamoto T. Diffuse mode of tumor cell invasion and expression of mutant p53 protein but not of p21 protein are correlated with treatment failure in oral carcinomas and their metastatic foci. Oncology 59 1 (2000) 36-43
28. Liu M., Lawson G., Delos M., Jamart J., Ide C., Coche E., et al. Predictive value of the fraction of cancer cells immunolabeled for proliferating cell nuclear antigen or Ki67 in biopsies of head and neck carcinomas to identify lymph node metastasis: comparison with clinical and radiologic examinations. Head Neck 25 4 (2003) 280-288